Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy - PubMed

Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy

Genguo Wang et al. Biomed Pharmacother. 2017 Dec.

Abstract

Although the eukaryotic translation initiation factor 4E (eIF4E) has been shown to be critically involved in the transformation and progression of various tumors, little is known about the role of eIF4E in retinoblastoma. In this work, we report that ribavirin, a pharmacologic inhibitor of eIF4E function, effectively targets retinoblastoma and angiogenesis. Ribavirin treatment dose-dependently blocked the growth and stimulated apoptosis in various retinoblastoma cell lines, with IC₅₀ values that are within the clinically achievable range. Ribavirin also significantly inhibited angiogenesis via disrupting capillary network formation and suppressing VEGF-induced migration, proliferation and survival of human retinal endothelial cells. In addition, ribavirin significantly augments chemotherapy agent's inhibitory effects in retinoblastoma in vitro and in vivo. Mechanistically, ribavirin inhibited eIF4E function in retinoblastoma cells as shown by the decreased protein levels of Cyclin D1, c-Myc and VEGF without affecting their mRNA expression. Overexpression of the wildtype and phosphormimetic but not the nonphosphorylatable form of eIF4E significantly abolished the inhibitory effects of ribavirin, further demonstrating eIF4E as the target of ribavirin. Genetic knockdown of eIF4E using two independent siRNAs mirrored ribavirin's effects, confirming the role of eIF4E in retinoblastoma growth, survival and response to chemotherapy. Our findings provide a preclinical rationale to explore ribavirin as a strategy to treat retinoblastoma and highlight the therapeutic value of targeting eIF4E in retinoblastoma.

Keywords: Angiogenesis; Retinoblastoma; Ribavirin; eIF4E.

Similar articles

• Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.

  Cao J, Sun X, Zhang X, Chen D. Cao J, et al. Clin Transl Oncol. 2018 Jun;20(6):761-767. doi: 10.1007/s12094-017-1786-z. Epub 2017 Oct 30. Clin Transl Oncol. 2018. PMID: 29086249

• Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.

  Tan J, Ye J, Song M, Zhou M, Hu Y. Tan J, et al. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7. J Biochem Mol Toxicol. 2018. PMID: 29112301

• Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.

  Liu Y, Sun L, Su X, Guo S. Liu Y, et al. Biomed Pharmacother. 2016 Dec;84:237-243. doi: 10.1016/j.biopha.2016.09.038. Epub 2016 Sep 20. Biomed Pharmacother. 2016. PMID: 27662474

• Targeting translation: eIF4E as an emerging anticancer drug target.

  Lu C, Makala L, Wu D, Cai Y. Lu C, et al. Expert Rev Mol Med. 2016 Jan 18;18:e2. doi: 10.1017/erm.2015.20. Expert Rev Mol Med. 2016. PMID: 26775675 Review.

• eIF4E expression in tumors: its possible role in progression of malignancies.

  De Benedetti A, Harris AL. De Benedetti A, et al. Int J Biochem Cell Biol. 1999 Jan;31(1):59-72. doi: 10.1016/s1357-2725(98)00132-0. Int J Biochem Cell Biol. 1999. PMID: 10216944 Review.

Cited by

• The Effect of MicroRNA-101 on Angiogenesis of Human Umbilical Vein Endothelial Cells during Hypoxia and in Mice with Myocardial Infarction.

  Pang J, Ye L, Chen Q, Wang J, Yang X, He W, Hao L. Pang J, et al. Biomed Res Int. 2020 Sep 3;2020:5426971. doi: 10.1155/2020/5426971. eCollection 2020. Biomed Res Int. 2020. PMID: 32953883 Free PMC article.

• Reciprocal Dynamics of Metabolism and mRNA Translation in Tumor Angiogenesis.

  Lidonnici J, Oberkersch RE. Lidonnici J, et al. Int J Mol Sci. 2024 Oct 20;25(20):11284. doi: 10.3390/ijms252011284. Int J Mol Sci. 2024. PMID: 39457064 Free PMC article. Review.

• Review: New horizons in retinoblastoma treatment: an updated review article.

  Azimi F, Mirshahi R, Naseripour M. Azimi F, et al. Mol Vis. 2022 Jul 11;28:130-146. eCollection 2022. Mol Vis. 2022. PMID: 36034735 Free PMC article. Review.

• Increased Angiogenesis by Exosomes Secreted by Adipose-Derived Stem Cells upon Lipopolysaccharide Stimulation.

  Wu SC, Kuo PJ, Rau CS, Huang LH, Lin CW, Wu YC, Wu CJ, Tsai CW, Hsieh TM, Liu HT, Huang CY, Hsieh CH. Wu SC, et al. Int J Mol Sci. 2021 Aug 18;22(16):8877. doi: 10.3390/ijms22168877. Int J Mol Sci. 2021. PMID: 34445582 Free PMC article.

• mTOR inhibition by TAK-228 is effective against growth, survival and angiogenesis in preclinical retinoblastoma models.

  Tang L, Fu Y, Song J, Hu T, Li K, Li Z. Tang L, et al. Pharmacol Res Perspect. 2022 Feb;10(1):e00930. doi: 10.1002/prp2.930. Pharmacol Res Perspect. 2022. PMID: 35142090 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • scite Smart Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program